Navigation Links
New Drug May Put the Squeeze on Heart Failure
Date:8/19/2011

By Denise Mann
HealthDay Reporter

THURSDAY, Aug. 18 (HealthDay News) -- An experimental heart failure drug may change the way doctors treat this vexing condition, researchers say.

Heart failure, also called congestive heart failure, occurs when the heart can no longer pump strongly enough for blood to the reach the rest of the body. About 5.7 million people in the United States have heart failure, and 300,000 people die from it each year, according to the U.S. National Heart, Lung, and Blood Institute. While no cure exists, treatments focus on improving quality of life and helping people live longer.

A new drug -- omecamtiv mecarbil, which is being developed by Cytokinetics Inc. in San Francisco -- may someday offer an alternative to current treatments, according to the results of two clinical trials published Aug. 20 in a special issue of The Lancet.

"It improves heart function in a completely new and unique manner," said Dr. John R. Teerlink, a cardiologist at the San Francisco Veterans Affairs Medical Center and author of one of the new studies.

"The drug directly increases the activation of certain heart muscle proteins, effectively recruiting 'more hands on the rope' with each heartbeat," he said. "By improving the efficiency and performance of the heart, it is our hope that patients with heart failure will actually feel better with fewer symptoms of fatigue and shortness of breath, and perhaps even live longer," he said.

However, it is too early to draw any sweeping conclusions, as the drug -- called a cardiac myosin activator -- is in the early stages of clinical trials.

The currently available heart failure drugs, such as milrinone (Primacor) and dobutamine (Dobutrex), indirectly increase heart function, and can cause dangerous, even deadly, heart rhythm abnormalities, Teerlink said. "These drugs are 'necessary evils' because they are the only currently available pharmacologic means to increase heart function," he said.

Teerlink's study involved 34 healthy men who received the drug intravenously once a week for one month. It was designed to determine the optimal dosing regimen for the new drug.

The other study, conducted at the University of Hull in East Yorkshire, England, marks the first time that the agent was studied in people with heart failure. The researchers said omecamtiv mecarbil safely improved cardiac function in 45 people with heart failure who were already receiving standard treatment.

Dr. Ronald Zolty, director of the heart failure program at the Albert Einstein College of Medicine in New York City, is cautiously optimistic about the new heart failure drug.

"It is a promising drug, but we have been down this road before," he said.

"When you have heart failure, the pumping action of the heart is weak, so not enough blood gets to the body, and you feel short of breath, sleep a lot and your kidneys don't work," Zolty explained.

Existing drugs do improve the "squeeze," but they also increase mortality, he said.

Dr. Michele Hamilton, director of the heart failure program at Cedars-Sinai Heart Institute in Los Angeles, agreed with Zolty on the need for a new heart failure drug.

"The major problem we face in treating heart failure is how can we make the heart squeeze harder," she said. To date, no medications have proven effective or safe, and as a result, doctors focus on getting rid of excess fluid buildup and reducing stress on the heart, she said.

Medications that make the heart squeeze harder put more stress on the heart, and the patients die sooner. "It is akin to whipping a tired horse as it goes uphill," she said.

"It's great to see a new medication being tested and developed," Hamilton said. But, "we are far away from the finish line."

More information

To learn more about heart failure, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Michele Hamilton, M.D., director, heart failure program, Cedars-Sinai Heart Institute, Los Angeles; John R. Teerlink, M.D., cardiologist, San Francisco Veterans Affairs Medical Center, San Francisco; Ronald Zolty, M.D., Ph.D., director, heart failure program, Albert Einstein College of Medicine, Bronx, N.Y.; Aug. 20, 2011, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Putting the squeeze on fat cells
2. ICU Patients at Risk for Rare Heart Rhythm Problem
3. Cook With Love This Valentines Day With Heart-Smart Recipes
4. Study finds racial gaps continue in heart disease awareness
5. Highmark Foundation Awards $120,000 to the American Heart Association
6. Womens Heart Disease Awareness Still Lacking
7. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
8. Migraine Linked to Increased Heart Attack Risk
9. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
10. Compound shows promise against intractable heart failure
11. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Put the Squeeze on Heart Failure
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: